SOHONOS (palovarotene)

Self-Administration – oral capsules

 

Diagnosis considered for coverage:

 

  • Fibrodysplasia Ossificans Progressiva (FOP): Indicated for reduction in the volume of new heterotopic ossification in adults and children aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP)

 

Coverage Criteria:

 

For diagnosis of Fibrodysplasia Ossificans Progressiva (FOP):

  • Diagnosis of Fibrodysplasia Ossificans Progressiva (FOP) AND

  • Prescribed in consultation with one of the following: Geneticist, Orthopedic physician, Rheumatologist, Endocrinologist AND
  • Molecular genetic testing confirms mutation in the ACVR1 gene AND
  • One of the following:
    • Patient is female and 8 years of age or older OR
    • Patient is male and 10 years of age or older

 

Reauthorization Criteria:

 

For diagnosis of Fibrodysplasia Ossificans Progressiva (FOP):

  • Patient demonstrates positive clinical response to therapy (e.g., reduction of volume in new abnormal bone growth) 

 

Coverage Duration: 

 

  • Initial: 3 months
  • Reauthorization: 12 months

 

Dosing: 

 

For diagnosis of Fibrodysplasia Ossificans Progressiva (FOP):

  • Daily dose: 
    • Recommended dosage for adults and pediatric patients 14 years and older is 5mg once daily, stop daily dosing when flare-up dosing begins
  • Flare up dose: 
    • Recommended flare up dosage for adults and pediatric patients 14 years and older is 20mg daily for 4 weeks, followed by 10mg daily for 8 weeks (total 12 weeks), even if symptoms resolve earlier, then return to daily dose of 5 mg
    • If during the course of flare-up treatment, the patient experiences marked worsening of the original flare-up site or another flare-up at a new location, restart the 12-week flare-up dosing at 20 mg daily.
    • For flare-up symptoms that have not resolved at the end of the 12-week period, the 10 mg daily dosage may be extended in 4-week intervals and continued until the flare-up symptoms resolve. If new flare-up symptoms occur after the 5 mg daily dosing is resumed, flare-up dosing may be restarted.
    • Recommended dosage for pediatric patients aged 8-13 years for females and aged 10-13 years for males:

 

Authorization is not covered for the following:


The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

 

Additional Information: 

 

  • Palovarotene is contraindicated in patients during pregnancy and has a boxed warning for embryo-fetal toxicity and PPC in growing pediatric patients.

 

Policy Updates:

 

  • 3/1/2024 (policy effective date)- New Sohonos Criteria (P&T 2/20/2024) (P&T meeting February) 

References:


1.    Sohonos Prescribing Information. Ipsen Biopharmaceuticals, Inc. Cambridge, MA. August 2023. 
2.    ClinicalTrials.gov. An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva. (MOVE). Available at: https://www.clinicaltrials.gov/study/NCT03312634?term=nct03312634&rank=1.
3.    UptoDate. Fibrodysplasia ossificans progressiva. Available at: https://www.uptodate.com/contents/fibrodysplasia-ossificans-progressiva?search=sohonos&source=search_result&selectedTitle=1~1&usage_type=default&display_rank=1. Accessed September 30, 2023. 
4.    Kaplan, F., Mukaddam, M. et al. The Medical Management of Fibrodysplasia Ossificans Progressiva: Current Treatment Considerations. August 2021. Available at: https://d3n8a8pro7vhmx.cloudfront.net/ifopa/pages/1042/attachments/original/1628698995/Guidelines_%28full_document%29.pdf?1628698995. Accessed September 30, 2023. 
5.    Kitok, H. Clinical Aspects and Current Therapeutic Approaches for FOP. September 2020. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555688/. Accessed September 30, 2023. 
6.    Fibrodysplasia Ossificans Progressiva. Available at: https://rarediseases.org/rare-diseases/fibrodysplasia-ossificans-progressiva/. August 2023. Accessed September 30, 2023. 
7.    Shaikh, U., Khan, A., et al. Novel Therapeutic Targets for Fibrodysplasia Ossificans Progressiva: Emerging Strategies and Future Directions. July 2023. Available at: https://www.cureus.com/articles/172507-novel-therapeutic-targets-for-fibrodysplasia-ossificans-progressiva-emerging-strategies-and-future-directions#!/. Accessed September 30, 2023. 
8.    Ipsen Biopharmaceuticals, Inc. Sohonos (palovarotene) capsule. 2023. [Updated 2023 Aug]. In: DailyMed[Internet].[2023]- National Library of Medicine (US). Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67dce406-7cc4-4d66-92de-ad18b6df0625
 

Last review date: March 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone